Silexion Therapeutics's Comment on Competition and Industry Peers
The company operates in the biotechnology, pharmaceutical, and oncology sectors and faces competition from major biotechnology and pharmaceutical companies, academic institutions, governmental agencies, and public and private research institutions. Competitors include entities developing or marketing cancer treatments, particularly KRAS inhibitors. Marketed KRAS G12C inhibitors are offered by Amgen and Bristol-Myers Squibb. Clinical-stage projects with pan-KRAS activity are pursued by Revolution Medicines, Chengdu Hyperway, GenFleet, Erasca (formerly Joyo), Jacobio/AstraZeneca, Pfizer, BeOne, Lilly, Amgen, Chugai (Roche), Astellas, BridgeBio Oncology, and Adlai Nortye. Additional companies in the competitive landscape include BioNTech, Roche, Merck/Moderna, Boehringer, and Gilead. Competitors often possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Early-stage companies and academic research institutions may also represent significant competition, particularly through collaborations with larger companies.
September 11, 2025
In a significant advancement for cancer treatment, Silexion Therapeutics announced promising preclinical results regarding its novel therapeutic candidate, SIL204. The company has demonstrated that SIL204 effectively reaches major metastatic sites in pancreatic cancer, specifically the liver, peritoneum, and lung, following systemic administration. This breakthrough offers hope for improving outcomes for patients battling one of the most challenging and often deadly forms of cancer.Pancreatic cancer is notorious for its aggressive progression and late-stage diagnosis, resulting in an alarmingly high mortality rate. Historically, therapeutic approaches for metastatic pancreatic cancer have been limited, prima...
March 3, 2025
In the ever-evolving landscape of biomedical innovation, Silexion Therapeutics (NASDAQ: SLXN) is on the verge of potentially groundbreaking advancements in the treatment of KRAS-driven cancers. Recently, PESG Research released a market update on Silexion that casts a spotlight on this pioneering biotech firm s meticulous journey and the anticipation surrounding its upcoming preclinical data. As Silexion approaches the release of initial results from its study on SIL-204 in orthotopic pancreatic cancer models, the biotech community closely watches to see if this milestone could solidify its standing at the forefront of cancer treatment innovations. Revolutionizing Cancer Treatment with RNAi Technology Based i...
January 15, 2025
In a significant advancement in cancer therapeutics, Silexion Therapeutics has recently released encouraging preclinical data regarding its investigational drug, SIL-204. This novel agent has exhibited impressive synergistic effects when combined with first-line chemotherapeutic agents commonly used in the treatment of pancreatic cancer, namely 5-fluorouracil, irinotecan, and gemcitabine. This revelation could be a pivotal step forward in addressing the formidable challenge posed by KRAS-mutated pancreatic cancer, a malignancy notoriously resistant to conventional therapies.Pancreatic cancer remains one of the most lethal forms of cancer, with a dismal five-year survival rate that underscores the urgent need...
October 1, 2024
GRAND CAYMAN, Cayman Islands Silexion Therapeutics Corp. (NASDAQ: SLXN) has announced a significant breakthrough in its ongoing efforts to develop treatments for KRAS-driven cancers. As a clinical-stage biotechnology firm specializing in RNA interference (RNAi) therapies, Silexion s latest findings on its second-generation siRNA candidate, SIL-204, mark a promising advancement in cancer treatment. The ExperimentThe company s recent preclinical studies focused on the optimized extended-release formulation of SIL-204, designed as microparticles. These studies aim to assess the candidate s ability to inhibit tumor growth and induce necrosis in KRAS-driven cancers. KRAS is one of the most frequently mutated o...
September 9, 2024
In the competitive landscape of precision oncology, Silexion Therapeutics (NASDAQ: SLXN) has begun to carve out a niche as a pioneering force in RNA interference (RNAi) therapy, particularly focusing on tackling the formidable challenge presented by KRAS-driven cancers. With the recent completion of its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion is now positioned to capitalize on the burgeoning demand for targeted cancer treatments, especially in the context of pancreatic cancer, known for its dire prognosis and limited treatment options. Understanding the Science At the heart of Silexion’s innovation is its application of RNAi technology, which works by silencing specific genes that dri...
Publicly Traded Peers of Silexion Therapeutics Corp
Sources:
Silexion Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Silexion Therapeutics Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
